Latest News

FDA Approves Abeona Therapeutics' Epidermolysis Bullosa Gene Therapy Pz-Cel
FDA Approves Abeona Therapeutics' Epidermolysis Bullosa Gene Therapy Pz-Cel

April 29th 2025

The agency's decision was based on data from the phase 3 VIITAL study (NCT04227106).

Cassandra Gorsuch, PhD, chief scientific officer at Precision
Cassandra Gorsuch, PhD, on the Durability and Next Steps for the ARCUS Gene Editing Platform in DMD

April 28th 2025

Linda Marbán, PhD, the CEO of Capricor Therapeutics
Evaluating Capricor’s Cardiomyopathy Cell Therapy Deramiocel for DMD

April 28th 2025

Cassandra Gorsuch, PhD, chief scientific officer at Precision
Cassandra Gorsuch, PhD, on the ARCUS Gene Editing Platform and Its Potential in DMD

April 27th 2025

CGTLive®’s Weekly Rewind
CGTLive®’s Weekly Rewind – April 25, 2025

April 25th 2025

Video Interviews

Conference Coverage

View All
Linda Marbán, PhD, the CEO of Capricor Therapeutics
Linda Marbán, PhD, on Evaluating Capricor’s Cardiomyopathy Cell Therapy Deramiocel for DMD

April 24th 2025

Natalie Goedeker, CPNP, on Handling Neuromuscular Gene Therapy at Real-World Sites
Natalie Goedeker, CPNP, on Handling Neuromuscular Gene Therapy at Real-World Sites

March 27th 2025

Sarepta’s DMD Gene Therapy Elevidys Demonstrates Manageable Safety Across 5-Year Timespan
Sarepta’s DMD Gene Therapy Elevidys Demonstrates Manageable Safety Across 5-Year Timespan

March 26th 2025

REGENXBIO’s DMD Gene Therapy RGX-202 Generates Microdystrophin Expression in Additional Patients Treated in Phase 1/2 Trial
REGENXBIO’s DMD Gene Therapy RGX-202 Generates Microdystrophin Expression in Additional Patients Treated in Phase 1/2 Trial

March 20th 2025

All News

© 2025 MJH Life Sciences

All rights reserved.